Special Issue "Novel Biomarkers and Mechanisms Underlying HBV and HDV Infection"
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 9060
Interests: HBV; HDV; HIV; SARS-CoV-2; diagnostics of viral diseases
Special Issues, Collections and Topics in MDPI journals
Hepatitis B virus (HBV) cannot be eliminated completely from infected hepatocytes since intrahepatic covalently closed circular DNA (cccDNA) persists in the liver of infected people. Unfortunately, estimation of the HBV intrahepatic reservoir is strongly limited by the need of liver biopsy.
In recent years, multiple novel non-invasive HBV have been emerging as affordable surrogate markers of the pool and activity of the HBV intrahepatic reservoir and could also reflect the extent of HBV–DNA integration within the DNA of infected hepatocytes. Indeed, these aspects are crucial to elucidate still the undefined pathogenic mechanisms that underly HBV and HDV infection and to assess properly the therapeutic response, also considering the upcoming introduction of novel anti-HBV therapies aimed to achieve functional HBV cure.
Innovative HBV biomarkers also represent promising tools for improved disease staging, HCC-risk stratification and anti-HBV therapy optimization in the setting of both HBV mono-infection and HBV co-infection with hepatitis delta virus (HDV).
In this light, this Special Issue aims to collect research articles and reviews on the pathogenic mechanisms that underly HBV and HDV infections and on innovative HBV biomarkers, with a special focus on the role of novel HBV biomarkers in reflecting viral intrahepatic reservoir characteristics and dynamics, as well as in predicting disease outcome in the setting of both HBV infection and HBV/HDV co-infection.
Dr. Romina Salpini
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hepatitis B
- hepatitis delta
- HBV novel markers
- intrahepatic HBV reservoir
- HBV integration